JD 123
Alternative Names: JD-123Latest Information Update: 19 Jan 2024
At a glance
- Originator Beijing JD Biotech
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase 0 Acute myeloid leukaemia
Most Recent Events
- 30 Dec 2023 Phase-0 clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in China (Parenteral) (NCT06201247)